Regulation of Btk function by a major autophosphorylation site within the SH3 domain.

Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development. Overexpression of Btk with a Src family kinase increases tyrosine phosphorylation and catalytic activity of Btk. This occurs by transphosphorylation at Y551 in the Btk catalytic domain and the enhancement of Btk autophosphorylation at a second site. A gain-of-function mutant called Btk* containing E41 to K change within the pleckstrin homology domain induces fibroblast transformation. Btk* enhances the transphosphorylation of Y551 by endogenous Src family tyrosine kinases and autophosphorylation at the second site. We mapped the major Btk autophosphorylation site to Y223 within the SH3 domain. Mutation of Y223 to F blocks Btk autophosphorylation and dramatically potentiates the transforming activity of Btk* in fibroblasts. The location of Y223 in a potential ligand-binding pocket suggests that autophosphorylation regulates SH3-mediated signaling by Btk.

[1]  M.,et al.  Involvement of p59fynT in interleukin-5 receptor signaling [published erratum appears in J Exp Med 1995 Oct 1;182(4):1179] , 1995, The Journal of experimental medicine.

[2]  J. Kinet,et al.  Activation of BTK by a Phosphorylation Mechanism Initiated by SRC Family Kinases , 1996, Science.

[3]  S. Schreiber,et al.  Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. , 1995, Science.

[4]  K. Arai,et al.  SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat , 1988, Molecular and cellular biology.

[5]  B. Neel,et al.  Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. , 1993, Analytical biochemistry.

[6]  Stuart L. Schreiber,et al.  Structure of the Pl3K SH3 domain and analysis of the SH3 family , 1993, Cell.

[7]  M. Saraste,et al.  Crystal structure of the SH3 domain in human Fyn; comparison of the three‐dimensional structures of SH3 domains in tyrosine kinases and spectrin. , 1993, The EMBO journal.

[8]  A. Kazlauskas.  Receptor tyrosine kinases and their targets. , 1994, Current opinion in genetics & development.

[9]  B. Roques,et al.  NMR structure of the N-terminal SH3 domain of GRB2 and its complex with a proline-rich peptide from Sos , 1994, Nature Structural Biology.

[10]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[11]  O. Witte,et al.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias , 1991, Molecular and cellular biology.

[12]  D J Rawlings,et al.  Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. , 1993, Science.

[13]  J. Fargnoli,et al.  Src family protein tyrosine kinases induce autoactivation of Bruton's tyrosine kinase , 1995, Molecular and cellular biology.

[14]  F. Alt,et al.  Defective B cell development and function in Btk-deficient mice. , 1995, Immunity.

[15]  J. Wang,et al.  Deletion of an N‐terminal regulatory domain of the c‐abl tyrosine kinase activates its oncogenic potential. , 1989, The EMBO journal.

[16]  Wendell A. Lim,et al.  Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains , 1995, Nature.

[17]  J. Cambier,et al.  Signal transduction by the B cell antigen receptor and its coreceptors. , 1994, Annual review of immunology.

[18]  K. Walsh.  The Protein Kinase Family , 1987 .

[19]  O. Witte,et al.  Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products , 1985, Molecular and cellular biology.

[20]  J. Brugge,et al.  Effects of SH2 and SH3 deletions on the functional activities of wild-type and transforming variants of c-Src , 1992, Molecular and cellular biology.

[21]  Hongtao Yu,et al.  Structural basis for the binding of proline-rich peptides to SH3 domains , 1994, Cell.

[22]  T. Hunter,et al.  Requirement for c-Src Catalytic Activity and the SH3 Domain in Platelet-derived Growth Factor BB and Epidermal Growth Factor Mitogenic Signaling* , 1996, The Journal of Biological Chemistry.

[23]  R. Perlmutter,et al.  Regulation of lymphocyte function by protein phosphorylation. , 1993, Annual review of immunology.

[24]  B. Howell,et al.  Deletion of the SH3 domain of Src interferes with regulation by the phosphorylated carboxyl-terminal tyrosine. , 1993, The Journal of biological chemistry.

[25]  D. Baltimore,et al.  N‐terminal mutations activate the leukemogenic potential of the myristoylated form of c‐abl. , 1989, The EMBO journal.

[26]  T. Watanabe,et al.  IL-5 receptor-mediated tyrosine phosphorylation of SH2/SH3-containing proteins and activation of Bruton's tyrosine and Janus 2 kinases , 1994, The Journal of experimental medicine.

[27]  R. Perlmutter,et al.  Impaired expansion of mouse B cell progenitors lacking Btk. , 1995, Immunity.

[28]  R. Hendriks,et al.  Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. , 1994, Human molecular genetics.

[29]  J. Fargnoli,et al.  Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Baltimore,et al.  Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl. , 1993, Oncogene.

[31]  T. Hirano,et al.  Association and activation of Btk and Tec tyrosine kinases by gp130, a signal transducer of the interleukin-6 family of cytokines. , 1995, Blood.

[32]  H. Varmus,et al.  Site-directed mutagenesis of the SH2- and SH3-coding domains of c-src produces varied phenotypes, including oncogenic activation of p60c-src , 1990, Molecular and cellular biology.

[33]  H. Iba,et al.  Activation of the transforming potential of p60c-src by a single amino acid change. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Paul,et al.  Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. , 1993, Science.

[35]  G. Superti-Furga,et al.  Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra‐ and intermolecular interactions. , 1995, The EMBO journal.

[36]  Ornella Parolini,et al.  Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia , 1993, Cell.

[37]  J. Schlessinger,et al.  Solution structure of the SH3 domain of phospholipase C-γ , 1993, Cell.

[38]  D. Bentley,et al.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases , 1993, Nature.

[39]  P. Sternberg,et al.  Similarity of sli-1, a regulator of vulval development in C. elegans, to the mammalian proto-oncogene c-cbl , 1995, Science.

[40]  A. Satterthwaite,et al.  Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. , 1995, Immunity.

[41]  T. Hunter,et al.  Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. , 1991, Methods in enzymology.

[42]  R. Lovering,et al.  X-linked agammaglobulinemia--gene cloning and future prospects. , 1993, Immunology today.

[43]  F. Cross,et al.  Low level of cellular protein phosphorylation by nontransforming overproduced p60c-src , 1985, Molecular and cellular biology.

[44]  K. Isselbacher,et al.  Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Ullrich,et al.  Structure of the N-terminal SH3 domain of GRB2 complexed with a peptide from the guanine nucleotide releasing factor Sos , 1994, Nature Structural Biology.

[46]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[47]  Jonathan A. Cooper,et al.  The when and how of Src regulation , 1993, Cell.

[48]  R. Lovering,et al.  The protein product of the c-cbl protooncogene is phosphorylated after B cell receptor stimulation and binds the SH3 domain of Bruton's tyrosine kinase , 1995, The Journal of experimental medicine.

[49]  K. Luo,et al.  Cyanogen bromide cleavage and proteolytic peptide mapping of proteins immobilized to membranes. , 1991, Methods in enzymology.

[50]  S. Stacker,et al.  Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease , 1995, Cell.

[51]  J. Zheng,et al.  Affinity and specificity requirements for the first Src homology 3 domain of the Crk proteins. , 1995, The EMBO journal.

[52]  L. Wicker,et al.  X-linked immune deficiency (xid) of CBA/N mice. , 1986, Current topics in microbiology and immunology.

[53]  P. Sigler,et al.  Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain , 1995, Cell.

[54]  O. Witte,et al.  Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking , 1994, Molecular and cellular biology.

[55]  O. Witte,et al.  Regulation of Btk by Src family tyrosine kinases , 1996, Molecular and cellular biology.

[56]  A. Ducruix,et al.  Crystal structure of the mammalian Grb2 adaptor. , 1995, Science.

[57]  Jonathan A. Cooper,et al.  Restriction of the in vitro and in vivo tyrosine protein kinase activities of pp60c-src relative to pp60v-src , 1985, Molecular and cellular biology.

[58]  O. Witte,et al.  The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function. , 1995, Seminars in immunology.